Expansion of autoimmune-prone marginal zone (MZ) B cells has been implicated in type 1 diabetes (T1D). To test disease contributions of MZ B cells in NOD mice, Notch2 haploinsufficiency (Notch2+/−) was introduced, but failed to eliminate the MZ, as it does in C57BL/6 mice. Notch2+/−/NOD have MZ B cell numbers similar to WT C57BL/6, yet still develop diabetes. To test whether BCR-signaling supports Notch2+/−/NOD MZ B cells, Bruton's tyrosine kinase (Btk)-deficiency was introduced. Surprisingly, MZ B cells failed to develop in Btk-deficient Notch2+/−/NOD mice. Expression of Notch2 and its transcriptional target, Hes5, were increased in NOD MZ B cells compared with C57BL/6 MZ B cells. Btk-deficiency reduced Notch2+/− signaling exclusively in NOD B cells, suggesting that BCR-signaling enhances Notch2 signaling in this autoimmune model. The role of BCR-signaling was further investigated using an anti-insulin transgenic BCR (125Tg). Anti-insulin B cells in 125Tg/Notch2+/−/NOD mice populate an enlarged MZ, suggesting that low level BCR signaling overcomes reliance on Notch2. Tracking clonotypes of anti-insulin B cells in H chain only VH125Tg/NOD mice showed that BTK-dependent selection into the MZ depends on strength of antigenic binding, while Notch2-mediated selection does not. Importantly, anti-insulin B cell numbers were reduced by Btk-deficiency, but not Notch2-haploinsufficiency. These studies show that: 1) Notch2-haploinsufficiency limits NOD MZ B cell expansion without preventing T1D, 2) BTK supports the Notch2 pathway in NOD MZ B cells, and 3) autoreactive NOD B cell survival relies on BTK more than Notch2, regardless of MZ location, which may have important implications for disease-intervention strategies.